A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
for Non-small Cell Lung Cancer
Drug: Intismeran autogene
68 locations incl. Anchorage
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06077760·Phase 3·Recruiting